// CRNA Interview Prep — Receptor Type Data

const RECEPTORS = [
  {
    id: "lgic",
    name: "Ligand-Gated Ion Channels",
    short: "Ionotropic Receptors",
    speed: "Milliseconds",
    location: "Cell membrane",
    structure: "Pentameric channel",
    mechanism: "Direct ion flux",
    amplification: "None (1:1 ion flow)",
    examples: "GABA-A, nACh, NMDA, Glycine, 5-HT3",
    prototypeDrug: "Propofol, Succinylcholine",
    color: "#3b82f6",
    linkedMeds: [{ id: "propofol", name: "Propofol", note: "GABA-A potentiator" },{ id: "etomidate", name: "Etomidate", note: "GABA-A modulator (α-β interface)" },{ id: "succinylcholine", name: "Succinylcholine", note: "nAChR agonist (depolarizing)" },{ id: "rocuronium", name: "Rocuronium", note: "nAChR antagonist (competitive)" },{ id: "vecuronium", name: "Vecuronium", note: "nAChR antagonist (competitive)" },{ id: "cisatracurium", name: "Cisatracurium", note: "nAChR antagonist (competitive)" }],
    futureMeds: "Ketamine, Midazolam",
    overview: [
      "Ligand-gated ion channels (LGICs) are transmembrane protein complexes that function as both receptor AND ion channel in a single macromolecule. Binding the ligand directly opens or closes the channel with no intermediary signaling molecules, making them the fastest-acting receptor class.",
      "The general structure consists of 4-5 protein subunits arranged around a central ion-conducting pore. Each subunit has an extracellular domain (ligand binding), transmembrane domains (forming the pore), and intracellular domains. This pentameric arrangement is characteristic of the Cys-loop superfamily, which includes GABA-A, nicotinic ACh, glycine, and 5-HT3 receptors.",
      "The key characteristic is speed: signal transduction occurs on a millisecond timescale. This is why LGICs mediate rapid neurotransmission, synaptic signaling, and muscle contraction -- processes that cannot wait for second messenger cascades.",
      "LGICs fall into two functional categories. Excitatory channels permit Na+ and/or Ca2+ influx, producing depolarization (examples: nicotinic ACh receptor at the NMJ, NMDA and AMPA glutamate receptors). Inhibitory channels permit Cl- influx, producing hyperpolarization (examples: GABA-A and glycine receptors).",
      "A critical distinction for anesthesia practice is allosteric modulation vs. direct agonism. Propofol, benzodiazepines, and barbiturates all act at the GABA-A receptor, but at different binding sites with different clinical profiles. Benzodiazepines bind the alpha-gamma interface and increase channel opening frequency. Barbiturates and propofol bind the beta subunit and increase channel opening duration. At high concentrations, propofol and barbiturates can directly open the channel even without GABA -- benzodiazepines cannot, which is why they have a ceiling effect and greater safety margin."
    ],
    cascade: [
      "The signaling cascade of LGICs is elegantly simple compared to other receptor types: ligand binds --> conformational change --> pore opens --> ions flow down their electrochemical gradient --> immediate change in membrane potential. There are no second messengers, no enzymatic amplification, and no intermediate signaling proteins.",
      "Ion selectivity is determined by the amino acid residues lining the channel pore. Negatively charged residues (glutamate, aspartate) attract cations (Na+, Ca2+, K+) and repel anions. Positively charged or neutral residues allow anion (Cl-) passage. The pore diameter and charge distribution together create a selective filter.",
      "For GABA-A receptors specifically: GABA binding at the alpha-beta subunit interface triggers a conformational change that rotates the M2 transmembrane helices, opening the central pore. Cl- ions flow inward (down their concentration gradient), driving the membrane potential more negative (hyperpolarization). This makes the postsynaptic neuron less likely to fire an action potential -- the basis of neural inhibition.",
      "Desensitization is a clinically important phenomenon: prolonged agonist exposure causes the receptor to enter a desensitized state -- the channel is closed despite the agonist still being bound. This is directly relevant to succinylcholine's Phase II block, where sustained depolarization at the NMJ leads to receptor desensitization and a clinical picture resembling non-depolarizing blockade."
    ],
    clinical: [
      { name: "GABA-A", subunits: "alpha(1-6), beta(1-3), gamma(1-3) -- most common: alpha1-beta2-gamma2", ions: "Cl- influx", drugs: "Propofol (beta subunit), Benzodiazepines (alpha-gamma interface), Barbiturates (beta subunit), Etomidate (alpha-beta interface), Volatile anesthetics", significance: "Primary target of most IV and inhaled anesthetics. Allosteric modulation increases Cl- conductance --> CNS depression." },
      { name: "Nicotinic ACh (NMJ)", subunits: "alpha2-beta-delta-epsilon (adult) or alpha2-beta-delta-gamma (fetal)", ions: "Na+/K+ (nonselective cation)", drugs: "Succinylcholine (depolarizing agonist), Rocuronium/Vecuronium/Cisatracurium (non-depolarizing antagonists)", significance: "ACh binds at alpha-delta and alpha-epsilon interfaces. Both sites must be occupied for channel opening. NMBAs block one or both sites." },
      { name: "Nicotinic ACh (Ganglionic)", subunits: "alpha3-beta4 (predominant)", ions: "Na+/K+ (nonselective cation)", drugs: "Trimethaphan (historical), Hexamethonium (historical)", significance: "Mediates fast synaptic transmission at autonomic ganglia. High-dose NMBAs can produce ganglionic blockade (e.g., tubocurarine --> histamine release + ganglionic block --> hypotension)." },
      { name: "NMDA Glutamate", subunits: "NR1 (obligatory) + NR2A-D", ions: "Ca2+, Na+ influx; K+ efflux", drugs: "Ketamine (channel pore blocker), Nitrous oxide, Magnesium (physiologic blocker)", significance: "Voltage-dependent Mg2+ block at resting potential. Requires both glutamate + glycine (co-agonist) for activation. Ketamine binds the PCP site inside the open channel pore." },
      { name: "5-HT3 (Serotonin)", subunits: "Homomeric (5-HT3A) or heteromeric (5-HT3A/B)", ions: "Na+/K+ (nonselective cation)", drugs: "Ondansetron, Granisetron, Palonosetron (antagonists)", significance: "Located in CTZ and vagal afferents. Antagonism is the primary mechanism of serotonin-receptor-targeted antiemetics for PONV." },
      { name: "Glycine", subunits: "alpha1-3, beta -- pentameric (alpha3-beta2)", ions: "Cl- influx", drugs: "Strychnine (antagonist -- convulsant poison), Volatile anesthetics (potentiators)", significance: "Major inhibitory receptor in spinal cord and brainstem. Mediates reciprocal inhibition of motor neurons. Also serves as co-agonist at NMDA receptors." },
      { name: "AMPA Glutamate", subunits: "GluA1-4 (tetrameric)", ions: "Na+/K+ (most subtypes exclude Ca2+)", drugs: "Perampanel (antagonist -- antiepileptic), volatile anesthetics (mild inhibition)", significance: "Mediates fast excitatory synaptic transmission throughout the CNS. Unlike NMDA receptors, AMPA channels open rapidly without requiring membrane depolarization or co-agonist binding. AMPA receptor activation provides the initial depolarization needed to relieve the Mg2+ block on NMDA receptors -- the two work in sequence during excitatory transmission." }
    ]
  },
  {
    id: "gpcr",
    name: "G-Protein Coupled Receptors",
    short: "GPCRs / Metabotropic Receptors",
    speed: "Seconds-minutes",
    location: "Cell membrane",
    structure: "7TM + G-protein",
    mechanism: "G-protein --> second messengers",
    amplification: "High (cascade)",
    examples: "alpha/beta adrenergic, opioid, V1/V2",
    prototypeDrug: "Norepinephrine, Morphine",
    color: "#2dd4bf",
    linkedMeds: [
      { id: "norepinephrine", name: "Norepinephrine", note: "alpha-1/beta-1 agonist" },
      { id: "vasopressin", name: "Vasopressin", note: "V1a/V2 agonist" },
      { id: "epinephrine", name: "Epinephrine", note: "Non-selective alpha+beta agonist" },
      { id: "phenylephrine", name: "Phenylephrine", note: "Pure alpha-1 agonist" },
      { id: "ephedrine", name: "Ephedrine", note: "Indirect NE release + direct alpha/beta" },
      { id: "atropine", name: "Atropine", note: "M2 muscarinic antagonist" },
      { id: "glycopyrrolate", name: "Glycopyrrolate", note: "M1/M2/M3 antagonist" },
      { id: "labetalol", name: "Labetalol", note: "alpha-1 + beta antagonist" },
      { id: "hydralazine", name: "Hydralazine", note: "NO/cGMP pathway vasodilator" }
    ],
    futureMeds: "Epinephrine, Phenylephrine, Dobutamine, Atropine, Glycopyrrolate, Fentanyl/Morphine, Albuterol",
    overview: [
      "G-Protein Coupled Receptors (GPCRs) are the largest and most therapeutically targeted receptor superfamily, with over 800 encoded in the human genome. An estimated 34% of all FDA-approved drugs act on GPCRs, making this the single most important receptor class for clinical pharmacology.",
      "The signature structure is seven transmembrane alpha-helical domains (7TM), with an extracellular N-terminus for ligand binding and an intracellular C-terminus for G-protein coupling. The transmembrane helices create a ligand-binding pocket within the membrane plane.",
      "The tripartite signaling unit is: Receptor --> G-protein --> Effector. The receptor itself has no enzymatic or channel activity. It acts as a molecular switch that activates a heterotrimeric G-protein (alpha, beta, gamma subunits) on the intracellular side.",
      "The G-protein cycle: (1) Inactive state: G-alpha bound to GDP, associated with G-beta-gamma complex. (2) Ligand binding triggers receptor conformational change, causing G-alpha to exchange GDP for GTP and dissociate from G-beta-gamma. (3) Both G-alpha-GTP and free G-beta-gamma activate downstream effectors. (4) G-alpha has intrinsic GTPase activity that hydrolyzes GTP back to GDP, causing reassociation with G-beta-gamma and resetting the cycle.",
      "The key characteristic is amplification: one activated receptor can activate many G-proteins, and each G-protein can activate many effector molecules. Signal is amplified at every step -- a single activated adenylyl cyclase can synthesize thousands of cAMP molecules. This is why small amounts of circulating catecholamines produce large physiologic responses. Timescale: seconds to minutes.",
      "There are four major G-protein families: Gs (stimulatory -- activates adenylyl cyclase), Gi (inhibitory -- inhibits adenylyl cyclase), Gq (activates phospholipase C), and G12/13 (activates Rho-GEF for cytoskeletal changes). Understanding which G-protein a receptor couples to is the single most important concept for predicting the clinical effect of any drug acting at GPCRs. Interview pearl: cholera toxin permanently activates Gs (locks it in GTP-bound state causing persistent cAMP production and secretory diarrhea), while pertussis toxin inactivates Gi (prevents GDP-GTP exchange, removing the inhibitory brake on adenylyl cyclase)."
    ],
    cascade: [
      "Gq-coupled receptors (alpha-1 adrenergic, V1a vasopressin, M1/M3 muscarinic): G-alpha-q activates phospholipase C (PLC), which cleaves PIP2 into IP3 + DAG. IP3 binds IP3 receptors on the sarcoplasmic/endoplasmic reticulum, triggering Ca2+ release from intracellular stores. Ca2+ binds calmodulin, which activates MLCK (myosin light chain kinase), leading to myosin light chain phosphorylation and smooth muscle contraction/vasoconstriction. DAG simultaneously activates PKC for additional phosphorylation events.",
      "Gs-coupled receptors (beta-1, beta-2 adrenergic, V2 vasopressin, D1 dopamine): G-alpha-s activates adenylyl cyclase, increasing cAMP production, which activates PKA. In the heart (beta-1): PKA phosphorylates L-type Ca2+ channels (increased Ca2+ influx --> increased contractility), phospholamban (increased SR Ca2+ reuptake --> increased lusitropy), troponin I, and HCN channels (increased chronotropy). In vascular smooth muscle (beta-2): PKA phosphorylates MLCK (inactivating it), producing vasodilation and bronchodilation. At V2 receptors: PKA triggers aquaporin-2 insertion into the collecting duct for water reabsorption.",
      "Gi-coupled receptors (alpha-2 adrenergic, M2 muscarinic, mu/delta/kappa opioid, D2 dopamine): G-alpha-i inhibits adenylyl cyclase, reducing cAMP and PKA activity. Additionally, the G-beta-gamma subunits directly activate GIRK channels (G-protein-gated inwardly rectifying K+ channels), producing K+ efflux, hyperpolarization, and reduced neuronal firing or heart rate (vagal M2). This is the mechanism behind opioid receptor signaling, alpha-2 presynaptic autoreceptor feedback, and dexmedetomidine's sedative/analgesic effect.",
      "G12/13-coupled receptors (thromboxane A2, thrombin/PAR-1): G-alpha-12/13 activates Rho-GEF, which activates the small GTPase RhoA. RhoA activates Rho kinase (ROCK), which promotes cytoskeletal rearrangement, stress fiber formation, and smooth muscle contraction. This pathway is particularly important for platelet shape change during aggregation and for certain vascular smooth muscle contraction mechanisms independent of the Ca2+/MLCK pathway.",
      "Signal termination -- Phosphodiesterases (PDEs): Both cAMP and cGMP are degraded by phosphodiesterases. PDE breaks cAMP into inactive AMP, and cGMP into GMP, terminating the signal. This is a critical drug target: milrinone (PDE3 inhibitor) prevents cAMP breakdown in cardiomyocytes, producing inotropy and lusitropy WITHOUT requiring beta-receptor activation -- this is why it works in beta-receptor-downregulated heart failure when dobutamine fails. Sildenafil (PDE5 inhibitor) prevents cGMP breakdown in pulmonary vascular smooth muscle, producing pulmonary vasodilation for pulmonary hypertension. Roflumilast (PDE4 inhibitor) is used in COPD.",
      "The nitric oxide (NO) / cGMP pathway: In endothelial cells, eNOS (endothelial nitric oxide synthase) converts L-arginine + O2 into citrulline + NO, stimulated by shear stress, increased intracellular Ca2+, and neurotransmitters (acetylcholine, bradykinin, histamine, substance P). NO is a volatile gas with a half-life of only 2-30 seconds that freely diffuses across cell membranes into adjacent smooth muscle cells. There, NO activates soluble guanylate cyclase (sGC), converting GTP to cGMP. cGMP activates protein kinase G (PKG), which inhibits Ca2+ release from the SR, decreasing intracellular Ca2+ and producing smooth muscle relaxation and vasodilation. Nitroglycerin and nitroprusside work by generating NO, which explains their rapid vasodilatory effects on coronary arteries, pulmonary arteries, and peripheral veins (decreased preload)."
    ],
    gTable: [
      { gType: "Gq", receptors: "alpha-1, V1a, M1/M3, H1, AT1", effector: "PLC", messengers: "IP3, DAG, Ca2+", kinase: "PKC, CaM kinase", effect: "Vasoconstriction, bronchoconstriction, secretion" },
      { gType: "Gs", receptors: "beta-1, beta-2, beta-3, V2, D1, H2, 5-HT4", effector: "Adenylyl cyclase (activate)", messengers: "cAMP (increase)", kinase: "PKA", effect: "Increased HR/contractility, vasodilation, bronchodilation" },
      { gType: "Gi", receptors: "alpha-2, M2, mu/delta/kappa opioid, D2, GABA-B, 5-HT1", effector: "Adenylyl cyclase (inhibit)", messengers: "cAMP (decrease)", kinase: "PKA (decrease)", effect: "Bradycardia, sedation, analgesia, decreased NE release" }
    ],
    clinical: [
      { system: "Heart", receptors: "beta-1 (Gs) -- chronotropy, inotropy, dromotropy. M2 (Gi) -- vagal slowing via GIRK channel K+ efflux." },
      { system: "Vasculature", receptors: "alpha-1 (Gq) -- vasoconstriction via Ca2+/MLCK. beta-2 (Gs) -- vasodilation via cAMP/PKA inactivating MLCK." },
      { system: "Lungs", receptors: "beta-2 (Gs) -- bronchodilation (albuterol target). M3 (Gq) -- bronchoconstriction." },
      { system: "Kidney", receptors: "V2 (Gs) -- aquaporin-2 insertion, water reabsorption. D1 (Gs) -- renal vasodilation (fenoldopam, low-dose dopamine)." },
      { system: "CNS", receptors: "mu-opioid (Gi) -- analgesia, sedation, respiratory depression. alpha-2 (Gi) -- sedation, sympatholysis (dexmedetomidine)." }
    ],
    receptorEffects: [
      { category: "Sympathetic alpha", gq: "alpha-1", gs: "N/A", gi: "alpha-2", effects: "alpha-1: contraction of vascular smooth muscle, pupillary dilator (mydriasis), bladder/intestinal sphincters. alpha-2: inhibits NE release (presynaptic autoreceptor), inhibits insulin release, inhibits lipolysis, induces platelet aggregation." },
      { category: "Sympathetic beta", gq: "N/A", gs: "beta-1, beta-2, beta-3", gi: "N/A", effects: "beta-1: increased HR (chronotropy), contractility (inotropy), conduction (dromotropy), renin secretion. beta-2: vasodilation, bronchodilation, uterine relaxation (tocolysis), insulin secretion, glycogenolysis, hypokalemia (increased cellular K+ uptake). beta-3: lipolysis, thermogenesis in skeletal muscle, bladder smooth muscle relaxation (mirabegron)." },
      { category: "Parasympathetic muscarinic", gq: "M1, M3", gs: "N/A", gi: "M2", effects: "M1: cognitive function, enteric nervous system. M2: decreased HR, decreased atrial contraction strength. M3: contraction of bladder, bronchi, pupillary sphincter (miosis), ciliary body (accommodation); increases secretions (lacrimal, sweat, salivary, gastric acid); intestinal peristalsis; endothelium-mediated vasodilation (via NO release)." },
      { category: "Histamine", gq: "H1", gs: "H2", gi: "N/A", effects: "H1 (Gq): bronchoconstriction, increased vascular permeability, mucus production, pruritus, pain. H2 (Gs): increased gastric acid secretion." },
      { category: "Dopamine", gq: "N/A", gs: "D1", gi: "D2", effects: "D1 (Gs): renal vasculature vasodilation, activation of striatum direct pathway. D2 (Gi): regulates cerebral neurotransmitter release, inhibits striatum indirect pathway." },
      { category: "Vasopressin", gq: "V1", gs: "V2", gi: "N/A", effects: "V1 (Gq): vascular smooth muscle contraction (vasoconstriction). V2 (Gs): aquaporin-2 insertion in renal collecting tubules (water reabsorption), increased vWF release." }
    ]
  },
  {
    id: "rtk",
    name: "Enzyme-Linked Receptors",
    short: "Receptor Tyrosine Kinases & Related",
    speed: "Minutes-hours",
    location: "Cell membrane",
    structure: "Single TM + kinase domain",
    mechanism: "Phosphorylation cascades",
    amplification: "Moderate",
    examples: "Insulin-R, EGFR, ANP-R, JAK-STAT",
    prototypeDrug: "Insulin",
    color: "#a855f7",
    linkedMeds: [],
    futureMeds: "Insulin, Heparin (indirect), Protamine",
    overview: [
      "Enzyme-linked receptors have a single transmembrane domain with an extracellular ligand-binding domain and an intracellular catalytic (enzymatic) domain. The receptor IS the enzyme -- ligand binding directly activates intracellular kinase activity without requiring G-proteins or ion flux.",
      "The most clinically relevant subtype is the receptor tyrosine kinase (RTK): ligand binding triggers receptor dimerization, followed by cross-phosphorylation of tyrosine residues on the intracellular domain. These phosphorylated tyrosines serve as docking sites for intracellular signaling proteins containing SH2 domains.",
      "The timescale is minutes to hours. These receptors primarily regulate growth, differentiation, metabolism, and cell survival rather than moment-to-moment physiology. This is why they are less commonly targeted by acute ICU medications but are critical for understanding insulin signaling, growth factors, and many chemotherapeutic agents (tyrosine kinase inhibitors like imatinib).",
      "Key subtypes include: Receptor tyrosine kinases (RTKs) such as insulin receptor, EGF receptor, VEGF receptor, and PDGF receptor. Receptor serine/threonine kinases: the TGF-beta receptor phosphorylates SMAD proteins on serine/threonine residues rather than tyrosine -- SMADs then dimerize and translocate to the nucleus to regulate gene expression controlling fibrosis, immune regulation, and wound healing. Receptor guanylyl cyclases: the ANP/BNP receptor directly catalyzes GTP to cGMP upon ligand binding (membrane-bound guanylate cyclase, distinct from the soluble guanylate cyclase activated by NO). And tyrosine kinase-associated receptors (JAK-STAT pathway): cytokine receptors (IL-2, IL-6, IFN, EPO, TPO, G-CSF, GH, prolactin) lack intrinsic kinase activity but associate with JAK kinases upon ligand binding -- JAK phosphorylation activates STAT proteins which dimerize and translocate to the nucleus for gene transcription."
    ],
    cascade: [
      "The RTK activation sequence using the insulin receptor as the primary example: (1) Insulin binds the extracellular alpha subunits, triggering a conformational change. (2) Intracellular beta subunits cross-phosphorylate each other on specific tyrosine residues (autophosphorylation). (3) Phosphotyrosines recruit IRS-1 (insulin receptor substrate) via SH2 domains. (4) IRS-1 activates PI3K, which converts PIP2 to PIP3. (5) PIP3 activates Akt/PKB. (6) Akt triggers GLUT4 transporter translocation to the cell membrane, enabling glucose uptake.",
      "Akt also activates glycogen synthase (promoting glycogen storage), inhibits gluconeogenesis, and promotes protein synthesis through the mTOR pathway.",
      "ICU/anesthesia relevance: insulin resistance in critical illness is driven by stress hormones (cortisol, epinephrine, glucagon) that antagonize insulin signaling at multiple points. Epinephrine directly suppresses insulin secretion (via alpha-2 receptors on beta cells) AND impairs downstream insulin signaling. This is why patients on vasopressor infusions, particularly epinephrine, often develop severe hyperglycemia requiring insulin drips. Understanding this cascade informs tight glycemic control protocols in the ICU."
    ],
    clinical: [
      { target: "Insulin Receptor", relevance: "Glucose management perioperatively, insulin drip protocols in ICU, stress hyperglycemia pathophysiology, tight glycemic control debates (NICE-SUGAR trial)." },
      { target: "ANP/BNP Receptor", relevance: "Natriuretic peptide system, nesiritide (recombinant BNP), BNP/NT-proBNP as heart failure biomarkers, cGMP-mediated vasodilation." },
      { target: "Tyrosine Kinase Inhibitors", relevance: "Perioperative considerations for oncology patients: drug interactions, impaired wound healing, bleeding risk, QTc prolongation (sunitinib), hypertension (bevacizumab/VEGF pathway)." },
      { target: "JAK-STAT Pathway", relevance: "Cytokine storm in sepsis, understanding IL-6/TNF-alpha signaling, newer immunomodulatory agents (tofacitinib, baricitinib), rationale for tocilizumab in severe COVID/cytokine storm." }
    ]
  },
  {
    id: "nuclear",
    name: "Intracellular (Nuclear) Receptors",
    short: "Transcription Factor Receptors",
    speed: "Hours-days",
    location: "Cytoplasm / Nucleus",
    structure: "Transcription factor",
    mechanism: "Gene transcription",
    amplification: "High (gene products)",
    examples: "Glucocorticoid-R, Thyroid-R, PPAR",
    prototypeDrug: "Dexamethasone",
    color: "#f59e0b",
    linkedMeds: [],
    futureMeds: "Hydrocortisone, Dexamethasone, Methylprednisolone, Levothyroxine",
    overview: [
      "Intracellular receptors are located inside the cell -- either in the cytoplasm or the nucleus -- NOT on the cell membrane. The ligand must be lipophilic enough to cross the plasma membrane to reach its receptor. This includes steroid hormones, thyroid hormones, vitamin D, and retinoids.",
      "The general mechanism: a lipophilic ligand diffuses through the membrane and binds to an intracellular receptor protein. The ligand-receptor complex acts as a transcription factor, binding to specific DNA response elements in the nucleus to activate or repress gene transcription. This leads to altered mRNA production and ultimately altered protein synthesis.",
      "The key characteristic is the slowest onset of all receptor types -- hours to days for full effect, because the mechanism involves gene transcription and new protein synthesis. This is why a single dose of IV dexamethasone doesn't produce its full anti-inflammatory effect for 4-6 hours.",
      "Type I receptors (cytoplasmic) normally reside in the cytoplasm bound to heat shock proteins (HSP90). Ligand binding causes HSP90 to dissociate. The receptor-ligand complex then translocates to the nucleus, dimerizes, and binds DNA hormone response elements (HREs). Examples: glucocorticoid receptor (GR), mineralocorticoid receptor (MR), estrogen receptor (ER).",
      "Type II receptors (nuclear) are already in the nucleus, typically bound to DNA as a heterodimer with RXR (retinoid X receptor), in a repressed state. Ligand binding causes a conformational change that releases corepressors and recruits coactivators, activating gene transcription. Examples: thyroid hormone receptor (TR), vitamin D receptor (VDR), PPAR receptors.",
      "Mnemonic for cytoplasmic (Type I) steroid receptor ligands -- PETCA: Progesterone, Estrogen, Testosterone, Cortisol, Aldosterone. Nuclear (Type II) receptors bind thyroid hormones (T3/T4) and calcitriol (vitamin D). A key structural detail: all nuclear receptors share a common domain architecture with a zinc-finger DNA-binding domain, a ligand-binding domain, and a transactivation domain."
    ],
    cascade: [
      "The glucocorticoid receptor pathway (most relevant for ICU/anesthesia): (1) Cortisol (or hydrocortisone/dexamethasone) crosses the cell membrane due to lipophilicity. (2) Binds the glucocorticoid receptor (GR) in the cytoplasm, causing HSP90 to dissociate. (3) The GR-cortisol complex dimerizes and translocates to the nucleus through nuclear pores. (4) Binds glucocorticoid response elements (GREs) on DNA.",
      "Transactivation: the GR-ligand complex upregulates anti-inflammatory proteins including lipocortin-1/annexin A1 (inhibits phospholipase A2, blocking arachidonic acid release), IkB-alpha (sequesters NF-kB in cytoplasm), and IL-10 (anti-inflammatory cytokine).",
      "Transrepression: the GR-ligand complex directly inhibits NF-kB and AP-1 transcription factors, suppressing production of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6), COX-2, iNOS, and adhesion molecules. This dual mechanism -- turning on anti-inflammatory genes AND turning off pro-inflammatory genes -- produces the potent anti-inflammatory and immunosuppressive effects.",
      "The net clinical effect also includes a permissive effect on catecholamine sensitivity: glucocorticoids upregulate adrenergic receptor expression. This is why hydrocortisone in refractory septic shock (ADRENAL, APROCCHSS trials) works not through direct vasoconstriction but by restoring adrenergic receptor responsiveness and suppressing the inflammatory cascade. The delayed onset of these gene-transcription-dependent effects explains why stress-dose steroids take hours to show benefit."
    ],
    clinical: [
      { target: "Glucocorticoid Receptor", relevance: "Stress-dose steroids in refractory septic shock (hydrocortisone 50mg q6h), perioperative steroid coverage for chronic steroid use/adrenal insufficiency, dexamethasone for PONV (4mg IV) and airway edema, methylprednisolone for spinal cord injury (NASCIS controversy -- largely abandoned). Cortisol's role in the physiologic stress response." },
      { target: "Mineralocorticoid Receptor", relevance: "Aldosterone's role in Na+/K+ balance via ENaC channels in the collecting duct. Fludrocortisone as adjunct in septic shock. Spironolactone/eplerenone in heart failure (RALES, EMPHASIS-HF trials)." },
      { target: "Thyroid Hormone Receptor", relevance: "Thyroid storm perioperative management (beta-blockade + thionamide + iodine + steroids), myxedema coma (IV levothyroxine + hydrocortisone), amiodarone-induced thyroid dysfunction (Type I: excess iodine; Type II: thyroiditis)." },
      { target: "PPAR Receptors", relevance: "Thiazolidinediones (pioglitazone) for diabetes via PPAR-gamma activation. Emerging relevance in critical illness metabolism and fibrates (PPAR-alpha) in dyslipidemia." }
    ]
  }
];

export { RECEPTORS };
